

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2019 (22.08.2019)



(10) International Publication Number
WO 2019/160501 A1

(51) International Patent Classification:

C07K 16/30 (2006.01) G01N 33/53 (2006.01)
A61K 39/395 (2006.01) A61P 35/00 (2006.01)

138648 (SG). **GOH, Angeline**; c/o Singapore Immunology Network (SIgN), 8A Biomedical Grove, Level 4, Immunos Building, Singapore 138648 (SG).

(21) International Application Number:

PCT/SG2019/050077

(74) Agent: **SPRUSON & FERGUSON (ASIA) PTE LTD**;
P.O. Box 1531, Robinson Road Post Office, Singapore
903031 (SG).

(22) International Filing Date:

12 February 2019 (12.02.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10201801219V 13 February 2018 (13.02.2018) SG

(71) Applicant: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **WANG, Cheng-I**; c/o Singapore Immunology Network (SIgN), 8A Biomedical Grove, Level 4, Immunos Building, Singapore 138648 (SG). **LOW, Lionel Jianrong**; c/o Singapore Immunology Network (SIgN), 8A Biomedical Grove, Level 4, Immunos Building, Singapore

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: ANTI-HER2 ANTIBODIES




Figure 15

(57) Abstract: The current invention relates to anti-HER2 monoclonal antibodies and chimeric antigen receptors comprising anti-HER2 antigen-binding domains. In particular, the disclosed antibodies are capable of inducing apoptosis in HER2-expressing cells. The current invention also relates to a pharmaceutical composition comprising said antibodies and its use thereof to treat cancer.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*